1. Interactive Perioperative Airway NPO, OCP Interaction & CPT/ICD-10 Billing Engine
Select the patient's active incretin agent, dosing phase, procedure/medication context, and primary metabolic comorbidity to generate a copy-ready perioperative NPO order, drug-interaction directive, and CPT/ICD-10-CM encounter coding block.
2. Multi-Society Perioperative Airway & Endoscopy Protocol (ASA / AGA / ASMBS / SAGES)
Delayed gastric emptying induced by GLP-1 receptor activation can result in retained solid gastric contents despite standard 8-hour fasting intervals, creating a risk of pulmonary aspiration during induction of general anesthesia or deep procedural sedation.
Rather than universally holding GLP-1 therapy in all stable patients (which risks perioperative hyperglycemia in T2D or rebound appetite), stratify every surgical or endoscopy candidate by tachyphylaxis phase and active vagal GI symptoms:
- High-Risk Cohort (Escalation Phase, High Dose, or Active GI Symptoms): Place patient on a 24-hour clear-liquid diet prior to the procedure (rather than standard 6-to-8-hour solid NPO), hold the weekly dose 7 days prior (or daily dose on the day of surgery) when clinically appropriate, and perform point-of-care gastric ultrasound (POCUS) or proceed with rapid-sequence induction (RSI) full-stomach airway precautions.
- Low-Risk Cohort (Stable Maintenance Dose >8-12 Weeks with Zero GI Symptoms): Vagal parasympathetic receptor desensitization (tachyphylaxis) partially restores baseline gastric emptying over time; coordinate 24-hour liquid diet modification with anesthesia and screen via pre-op Bristol Stool & Vagal Motility Log (Patient Tool 04).
3. Oral Contraceptives (OCPs), Levothyroxine & Narrow-Therapeutic-Index Medications
Because incretin agonists slow antroduodenal motility, any co-administered oral medication that depends on rapid peak concentration (`Cmax`) or narrow absorption windows requires proactive clinical management:
- Oral Contraceptives (OCPs) — Critical Tirzepatide vs. Semaglutide Distinction: Following a single 5 mg dose of Tirzepatide, oral ethinylestradiol/levonorgestrel `Cmax` drops by 55% to 66% and `AUC` decreases by 16% to 20% with a 2.5-to-4.5-hour delay in `Tmax` (FDA Zepbound/Mounjaro Prescribing Information, Section 7.2). Instruct patients on Tirzepatide to switch to a non-oral contraceptive (IUD, implant, transdermal patch, vaginal ring) OR add a barrier contraceptive method for 4 weeks after initiation and for 4 weeks after EVERY dose escalation. Subcutaneous Semaglutide did not demonstrate clinically significant reductions in total OCP exposure in clinical pharmacology trials, though severe vomiting (>24 hours) on any agent compromises oral pill absorption.
- Levothyroxine (LT4) & Thyroid Hormone Recalibration: Delayed gastric emptying combined with a 15% to 22% reduction in total body mass alters levothyroxine volume of distribution and clearance. Administer LT4 on an empty stomach 30 to 60 minutes before breakfast (separated by ≥4 hours from iron or calcium/magnesium supplements) and re-check TSH and Free T4 every 6 to 8 weeks after ≥10% body-weight reduction to prevent iatrogenic subclinical hyperthyroidism (atrial fibrillation and cortical bone loss risk).
- Warfarin, Direct Oral Anticoagulants & Calcineurin Inhibitors: Monitor INR within 7 to 14 days of initiating or escalating any GLP-1/GIP therapy in patients taking warfarin, and monitor trough levels for narrow-therapeutic-index oral immunosuppressants (tacrolimus, cyclosporine) or anti-epileptics.
For detailed perimenopause transdermal HRT and PCOS endocrine co-management, open Track II Module 04: Female Neuro-Endocrine Co-Management (Perimenopause, HRT & PCOS) →
4. ICD-10-CM Diagnosis, CPT Evaluation/Management, MNT & Chronic Care Coding Reference
Defensible medical-necessity documentation and clinic sustainability require pairing accurate metabolic ICD-10-CM codes with Evaluation & Management (E/M), Medical Nutrition Therapy (MNT), and Chronic Care Management (CCM) CPT codes:
| Coding Category | Canonical Code(s) | Clinical Documentation & Medical Necessity Standard |
|---|---|---|
| Obesity & Adiposity (ICD-10-CM) | E66.01, E66.9, E66.3 + Z68.27-Z68.45 |
Always record both baseline pre-treatment BMI and current BMI alongside Waist-to-Height Ratio (>0.50) to protect continuation-of-care prior authorizations once BMI drops below 27 or 30 kg/m². |
| Insulin Resistance, PCOS & Cardiometabolic (ICD-10-CM) | E88.81 (Metabolic Syndrome/IR), E11.9 (T2D), E28.2 (PCOS), E78.5 (Dyslipidemia), I10, G47.33 (OSA), K76.0 (MASLD) |
Document objective fasting insulin (μIU/mL), calculated HOMA-IR = (Insulin × Glucose) / 405, ApoB (mg/dL), Triglyceride:HDL ratio, AHI (for OSA), or hepatic steatosis imaging. |
| Outpatient E/M Complexity or Time (CPT) | 99204 / 99205 (New)99214 / 99215 (Established) |
Supported by Moderate-to-High Medical Decision Making (MDM): prescription drug management (incretin titration + side-effect risk review) plus interpretation of independent biomarker panels and multi-comorbidity co-management. |
| Medical Nutrition Therapy (CPT MNT) | 97802 (Initial, per 15 min)97803 (Re-assessment)97804 (Group MNT) |
Document individualized calculation of the 1.2 to 1.6 g/kg/day protein floor, the 2.5g-3.0g Leucine Anchor per meal, and Ileal Brake meal sequencing to prevent sarcopenic lean mass loss. |
| Chronic Care & Remote Telemetry (CPT CCM) | 99490 (First 20 min clinical staff)99439 (+20 min add-on)99491 (Physician 30 min) |
Applicable when co-managing ≥2 chronic conditions (e.g., Obesity E66.01 + Hypertension I10 or Metabolic Syndrome E88.81) with structured monthly review of patient motility, protein, and Signal Volume logs. |
5. GLP-1 Perioperative, Contraceptive & Co-Medication Interaction Matrix
| Clinical Domain / Co-Medication | Pharmacokinetic / Physiological Mechanism | Quantified Clinical Threshold / Risk Window | Mandatory Prescriber Action |
|---|---|---|---|
| Elective Anesthesia & Endoscopy (ASA/AGA) | Vagal afferent & enteric GLP-1R delayed solid gastric emptying | Highest during Weeks 1-16 dose escalation or when Bristol Types 1-2 / nausea present | Prescribe 24-hr clear-liquid diet pre-op, coordinate POCUS gastric ultrasound, and apply RSI airway precautions if gastric contents present. |
| Oral Contraceptive Pills (OCPs) on Tirzepatide | GIP/GLP-1 delayed gastric emptying lowers oral steroid Cmax & AUC | -55% to -66% Cmax and -16% to -20% AUC after initial & escalated doses | Switch to non-oral contraception (IUD, implant, patch, ring) OR add barrier backup for 4 weeks after initiation and 4 weeks after EVERY dose escalation. |
| OralSemaglutide (SNAC) vs. Orforglipron | Gastric SNAC buffer absorption vs. non-peptide small molecule | Oral Semaglutide requires ≤4 oz water + 30-min fast; Orforglipron requires zero fasting | Separate Oral Semaglutide by ≥30 min from levothyroxine or bisphosphonates; Orforglipron (CYP3A4 substrate) avoids food/water timing restrictions. |
| Levothyroxine (LT4) During Weight Reduction | Altered gastric transit + reduced lean/adipose volume of distribution | ≥10% total body-weight reduction alters LT4 requirement | Re-check TSH and Free T4 6 to 8 weeks after every 10% weight loss; titrate LT4 down if TSH is suppressed (<0.4 mIU/L). |
6. Uncoordinated Episodic Prescribing vs. Risk-Stratified Perioperative & Co-Medication Management
Missed OCP Backup, Last-Minute Surgical Cancellations & Denials
Escalates Tirzepatide without warning reproductive-age patients about the 4-week oral contraceptive Cmax drop, gives zero 24-hour liquid-diet instructions prior to colonoscopy or elective surgery, and submits single-BMI chart notes that trigger insurance continuation denials.
Proactive Airway Stratification, 4-Week OCP Counseling & Dual-BMI Coding
Embeds automatic 4-week OCP backup alerts at every Tirzepatide dose step, stratifies surgical candidates with 24-hour liquid diet and POCUS protocols, re-checks TSH/Free T4 at 10% weight loss, and documents dual baseline/current BMI + HOMA-IR in every EHR note.
7. Frequently Asked Perioperative, Interaction & Billing Questions
What is the 2024/2026 ASA/AGA multi-society perioperative protocol for patients on GLP-1 receptor agonists?
Under the multi-society consensus guidance (ASA, AGA, ASMBS, ISPCOP, SAGES), patients during the dose-escalation phase, on higher maintenance doses, or with active GI symptoms (nausea, vomiting, bloating, abdominal pain) should be placed on a 24-hour clear-liquid diet prior to elective anesthesia or endoscopy and evaluated with point-of-care gastric ultrasound or full-stomach rapid-sequence induction (RSI) precautions.
Why does Tirzepatide require a 4-week oral contraceptive backup window while Semaglutide does not?
Tirzepatide delays gastric emptying most potently after the initial dose and each subsequent dose escalation, reducing oral ethinylestradiol/levonorgestrel Cmax by 55% to 66% and AUC by ~20% (FDA Zepbound/Mounjaro Section 7.2). Patients using oral contraceptives must switch to a non-oral contraceptive or add barrier backup for 4 weeks after initiation and for 4 weeks after every dose escalation.
When should levothyroxine (LT4) dosing be re-evaluated in a patient losing weight on GLP-1 therapy?
Re-check serum TSH and Free T4 every 6 to 8 weeks after a patient achieves a 10% or greater reduction in total body weight, or earlier if resting tachycardia, tremor, insomnia, or heat intolerance develops, as reduced body mass lowers total levothyroxine requirement.
Which ICD-10-CM and CPT codes support combined medical-nutritional GLP-1 co-management?
Pair primary metabolic ICD-10-CM diagnoses (E66.01, E66.9, E11.9, E88.81, E28.2, E78.5, I10, G47.33, Z68.30-Z68.45) with Complexity/Time E/M codes (99204/99205, 99214/99215), Medical Nutrition Therapy codes (97802-97804) for the 1.2-1.6 g/kg protein floor, and Chronic Care Management (99490/99439) for structured between-visit telemetry.